[Review Article]

Clinical importance of immunonutrition in infants: a review of the recent literature

Ji Sook Park, MD
Department of Pediatrics, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea
Institute of Health Sciences, Gyeongsang National University, Jinju, Korea

Running title: Immunonutrition for infants

Corresponding author: Ji Sook Park, MD, PhD
Department of Pediatrics, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, 15 Jinju-daero 816beon-gil, Chiram-dong, Jinju, Gyeongsangnam-do, Korea, 52727
Email: csassi@gnu.ac.kr
https://orcid.org/0000-0002-4704-2246
Abstract

During the last decades, the role of nutrition has been well elucidated in medicine, especially among critically ill infants and children. Many nutrients have the potential to modulate the immune system. A healthy immune system is essential for the prevention and recovery of many pediatric illnesses. Intervention using specific nutrients for the immune system is called immunonutrition. Immunonutrient supplementation has been attempted to modulate inflammatory or immune responses, leading to an improved clinical course of critically ill patients with prolonged nutritional supplementation parenterally or enterally. This review discusses immunomodulatory nutrients for infants based on the recent literature.

Key words: Immune system, Infant, Immunomodulation, Nutrient
Key message

Nutrients are important in the developing immune system. Human milk supplies diverse bioactives to prevent acute infection or chronic inflammation. Immunoglobulins, lactoferrin and glutamine in human milk decrease gastrointestinal and respiratory infection. Human milk oligosaccharides promote the growth of intestinal microbiota, the gut barrier, and antimicrobial or antiviral activity. Micronutrients act as anti-inflammatory immunonutrients, too. However, the toxicity of some nutrients from an overdose should be considered.

Graphical abstract

![Graphical abstract diagram]

- **Human milk**: Immunoglobulins, Lactoferrin, Glutamine, LCPUFAs, HMOs, human milk microbiota
- **Micronutrients**: Fe, Zn, Vitamins...
- **Feeding strategy for preterm infants**: Human milk, early enteral feeding, probiotics...

Immunonutrition for Infants
Introduction

Nutrition is essential in pediatric growth and development. It also plays a pivotal role in preventing and improving outcomes of diverse diseases in pediatric patients by maintaining an optimal immune response.\(^1\) Nutrition and the immune system are closely correlated. Nutritional intervention that has a direct or indirect immunologic effect is called immunonutrition.\(^2\) The concept of immunonutrition differs from that of folklore medicines or foods based on individual experiences and religious faiths that are not proven via the scientific process.\(^3\)

The immune system is immature at birth, but passive immunity transmitted from the mother through the placenta and the breastmilk can protect against infection in the neonatal period.\(^4\) Negative nutritional alterations during the prenatal or neonatal period can lead to immunologic changes, increasing the risk of infection earlier in life and chronic inflammatory disease later in life. Early-life nutritional exposure is a significant determinant of immune health.\(^5\) The present review aimed to discuss the immunological role of several nutrients for infants to prevent infectious diseases or non-communicable diseases later in life based on the recent scientific literature.

Human milk

Human milk, the first food, delivers diverse nutritional and immunologic factors to neonates that contribute to development of the immune system.\(^4\) As an optimal and exclusive nutritional source, it is recommended for all infants from birth to 6 months of age.\(^6\) Human milk contains immunologic, protective, and trophic components such as immunoglobulins, immune-regulatory cytokines, microbiologic factors, and diverse cell types (Table 1).\(^3,7\) The immunologic and diverse components of human milk support the immature immune system in
neonates and feature many immunonutritive benefits for infants. Breastfeeding, especially the duration of exclusive breastfeeding, is related with decreased gastrointestinal and respiratory infections in early life. It can also promote optimal health outcomes in later life.

1. Immunoglobulins

Immunoglobulin (Ig) A, IgG, IgM, and IgE are found in human milk. The most abundant Ig is secretary IgA (sIgA), followed by secretary IgG. SIgA in human milk is not fully digested by gastric acid in preterm or term infants. It provides lower gastrointestinal immunity and prevents the binding of toxins, bacteria, and viruses to the intestinal mucosa by neutralizing them. Although sIgA in human milk decreases over time, its production in breastfed infants increases over the first 6 months of life. IgG is the main immunoglobulin in the blood. It is also present in human milk, albeit at low levels. However, IgG levels tend to increase in human milk as breastfeeding continues. Several studies suggest the possibility of IgG in human milk as a protective role in decreasing infections in breastfed infants. Human milk can transfer IgM to infants. Term infants can partially digest IgM, whereas preterm infants cannot digest IgM. Human milk also contains allergen-specific IgG and IgE, immunoglobulins that may help sensitize infants.

2. Lactoferrin

Lactoferrin is a rich whey protein in human milk that binds well with iron. Lactoferrin in human milk is known to prevent bacterial, fungal, and viral infections. As iron is essential for microorganism growth, the iron-binding affinity of lactoferrin may inhibit bacterial growth by competing with bacteria to bind iron. However, the reported protective effects of recombinant or bovine lactoferrin are conflicting.
3. Glutamine

Glutamine, which is abundant in human milk, has been considered a fuel for rapidly dividing enterocytes and immune cells. It is a conditionally essential amino acid in critically ill patients, especially preterm infants.\textsuperscript{20,22} A blinded randomized study reported that glutamine supplementation for one month can reduce the rate of sepsis in preterm infants by blunting HLA-DR\textsuperscript{+} and CD16\textsuperscript{+} T lymphocytes.\textsuperscript{23} Glutamine has been theoretically considered to prevent necrotizing enterocolitis (NEC), but recent well-designed randomized controlled trials have not proven the benefit of glutamine supplementation for reducing NEC rates.\textsuperscript{8}

4. Long-chain polyunsaturated fatty acids

Human milk contains a considerable amount of long-chain polyunsaturated fatty acids (LCPUFAs). Linoleic acid (LA; 18:2n-6) and alpha-linolenic acid (ALA; 18:3n-3) are essential LCPUFAs that can modulate diverse immune responses in the body via lipoxins, prostaglandins, and thromboxanes.\textsuperscript{24} LCPUFA supplementation can significantly reduce bronchopulmonary dysplasia (BPD) and NEC in preterm infants by downregulating platelet-activating factor (PAF) and PAF receptor and by downregulating endotoxin translocation into the systemic circulation.\textsuperscript{20,24} It can also help develop retinal and cognitive function in infants.\textsuperscript{25,26} The mean levels of arachidonic acid (AA) and docosahexaenoic acid (DHA) in human milk are about 0.5\% and 0.3\% of total fatty acids, respectively, but the ratio of AA/DHA in mature human milk is considerably variable depending on a mother’s diet and region.\textsuperscript{27} Both DHA and AA are included in infant formula at amounts at least equal to DHA in human milk.\textsuperscript{27} However, the recommended dosages or ratios remain unclear.

5. Human milk oligosaccharides
Human milk oligosaccharides (HMOs) is the third most abundant substance in human milk, followed by lactose and lipids. The profiles of HMOs are quite diverse, with more than 200 distinct structures that differ from those of other mammals. The secretor (Se) and Lewis (Le) genes determine HMO diversity. HMOs are not digested by gastric acid and act as prebiotics by stimulating the growth of intestinal microbiota. The interaction of HMOs occurs mainly in Bifidobacterium infantis, Bifidobacterium bifidum, Bacteroides fragilis, and Bacteroides vulgatus. Another commensal bacteria, Escherichia coli, benefits indirectly from HMOs using metabolites from B. fragilis when HMOs are degraded. HMOs also provide antimicrobial activities by increasing the sensitivity of Group B Streptococcus, Staphylococcus aureus, or Acinetobacter baumannii to antibiotics. They also provide antiviral activity against rotavirus, norovirus, influenza, and human immunodeficiency virus by interacting with immune cells and inhibiting viral invasion. In addition, as an anti-pathogen, 2′-fucosyllactose (FL) of HMOs acts as a soluble decoy receptor for Campylobacter jejuni and reduces colonization. Lacto-N-fucopentaose (LNFP) I and 2′-FL reduce enteropathogenic E. coli adhesion and reduce pathogenicity by binding to heat-labile enterotoxin type 1. HMOs improve gut barrier function by promoting epithelial cell maturation via short-chain fatty acids, microbiota metabolites of HMOs, and glycocalyx alterations. They can also enhance the local and systemic immune system by inhibiting Toll-like receptors and interacting with dendritic cells, leading to T-cell proliferation. HMOs as immunonutrients play a role in promoting healthy gut microbiota, protecting against bacterial and viral infections, improving gut barrier function, and optimizing immune function. Therefore, HMOs play a potential role in preventing infection and allergic diseases (Table 2). Therefore, HMOs play a potential role in preventing infection and allergic diseases (Table 3).

6. Human milk microbiota
The initial formation of neonatal intestinal microbiota depends on maternal microbiota via adherence to intestinal cells and suppression of inflammation by the interaction with dendritic cell and the induction of T regulatory cell production.\textsuperscript{46} The maternal microbiota is affected by diverse conditions, such as the prenatal use of antibiotics, health status, body mass index, and gestational age.\textsuperscript{47} The complex human milk microbiota changes over time and varies among mothers. However, they generally include \textit{Bifidobacterium} and \textit{Lactobacillus} spp, \textit{Streptococcus}, \textit{Staphylococcus}, \textit{Bacteroides}, and \textit{Enterobacter}.\textsuperscript{46,47} The human milk microbiota can contribute to establishing healthy intestinal bacteria in neonates and infants. \textit{Lactobacillus} in the human milk induces Th1 cytokines and natural killer cells. They can adhere to intestinal cells, leading to the increased colonization of beneficial bacteria and the inhibition of pathogenic adhesion in the gut.\textsuperscript{48,49} \textit{Bifidobacterium} may suppress interleukin-8 in the presence of pathogenic \textit{Salmonella}\textsuperscript{50} and \textit{Bacteroides} may suppress inflammation in the laminar propria by increasing FOXP3 T cells using surface polysaccharide A.\textsuperscript{51} Although human milk contains diverse beneficial microbiota, intestinal microbiota compositions differ between infants fed expressed human milk and those directly breastfed. The intestinal microbiota of expressed breastmilk–fed infants show higher amounts of potential pathogens such as \textit{Enterobacteriaceae} but lower amounts of \textit{Bifidobacterium}.\textsuperscript{47,52} Human milk plays crucial roles in preventing infections and influencing long-term health like obesity or allergic diseases via diverse immune mechanisms.\textsuperscript{45} However, further research is required regarding the combined effect of bioactive supplementation in formula.

**Micronutrients**

1. Iron
Infants and children with iron deficiency can be susceptible to infections due to impaired T cell function which is associated with decreased production of interleukin 2. Iron supplementation can reverse the T cell dysfunction.

2. Zinc

Zn, the second most abundant metal in the human body following Fe, is a cofactor involved in DNA synthesis and repair. It is fundamental in protein synthesis as well as cell growth and differentiation. Zn deficiency occurs in acrodermatitis enteropathica, chronic malabsorption such as short bowel syndrome, or long-term insufficient supplementation of total parenteral nutrition. Inadequate Zn intake increases diarrhea and pneumonia, especially in children younger than 5 years of age, and Zn supplementation can reduce the duration of diarrhea and respiratory illnesses. Zn acts as a signaling molecule in the immune system. Zn deficiency induces lymphopenia caused by decreased B cell differentiation in the bone marrow and interferon-γ production.

3. Vitamins

Vitamins act as antioxidants by suppressing reactive oxygen radicals and activating antioxidant enzymes. Antioxidants can play important roles in the immune response via phagocytic function, cytokine and immunoglobulin production, and cell-mediated responses. Oxidative stress or free radicals are involved in the development of diverse illnesses including chronic inflammatory diseases, aging, and cancers. Vitamin E is a membrane-bound antioxidant that can act as a free radical scavenger that prevents damage from lipid peroxidation. When vitamin E deficiency is caused by chronic cholestasis or a chronic malabsorptive state, decreased activities of antioxidative enzymes and increased hepatic lipid peroxidation can occur. Vitamin
C, a hydrophilic antioxidant that cannot be synthesized by the human body, acts as a cofactor in collagen synthesis by activating hydroxylase by reducing Fe$^{3+}$ to Fe$^{2+}$. It is involved in inhibition of the redox potential under oxygen radical reactions in the body. Excess free radical generation and oxidant cellular damage have been postulated in the pathogenesis of NEC in preterm infants and inflammatory bowel disease in children and adults. Although further clinical studies are necessary, vitamins can be used as antioxidant and immunologic nutrients.

**Immunonutrition for preterm infants**

Preterm infants are vulnerable nutritionally and immunologically because they are more susceptible to unstable clinical conditions than term infants. Therefore, immunonutrition is more important for preterm than term infants. Immunonutritional clinical strategies can focus on preventing inflammatory or infectious issues that might be encountered in a neonatal intensive care unit. These strategies include feeding human milk (due to its diverse immunologic bioactive substances), providing early and fast advancement of enteral feeding, and minimizing iatrogenic harm. Although further research is needed to determine the appropriate strain, effective dosage, clinical approval, and quality and safety issues, the probiotics, prebiotics, or synbiotics supplementation to prevent NEC or sepsis could be an immunonutritional strategy for premature infants.

**Immunonutrition during the coronavirus disease 2019 pandemic**

During the coronavirus disease 2019 (COVID-19) pandemic, the whole world is struggling to find treatment regimens and effective vaccines based on immunologic knowledge. Immunonutrition is emerged as an adjuvant dietary supplementation technique. Although
severe acute respiratory syndrome coronavirus 2 is thought to be transmitted mainly via the respiratory route, gastrointestinal symptoms are often manifested at first in infants, suggesting that it can invade enterocytes.\textsuperscript{66} Early human milk feeding can promote an intestinal environment of tight enterocyte junctions by diverse bioactive substances and can contribute to reinforcing innate defense in neonates and infants. Therefore, early breastfeeding may provide prevention during the viral pandemic.\textsuperscript{67} Clinical trials using a combination of dietary supplements such as vitamin C, vitamin D, probiotics, and Zn are currently in progress.\textsuperscript{55} The clinical and theoretical effects of nutrients on the immune system based on immunonutrition during this pandemic are very attractive. However, clinical and preclinical data are quite limited, and more well-designed studies are necessary.

**Conclusion**

Human milk is a major source of immunonutrients for healthy and sick babies. Bioactive substances in human milk can support neonatal and infantile immune systems directly and indirectly. HMOs are likely to have prebiotic effects that can enhance the colonization of beneficial intestinal bacteria. However, adding HMOs to standard or preterm formula requires more detailed future studies. Many micronutrients and vitamins may be supplemented as anti-inflammatory immunonutrients for infants. However, the toxicity of some nutrients from an overdose should be considered. Extensive studies of the effects of immunonutrients in the developing immune system have been performed (Tables 2 and 3). Moreover, during this viral pandemic, the scientific interest in immunonutrition is increasing and further research is warranted to determine its clinical applications.
Footnotes

Conflicts of interest: No potential conflict of interest relevant to this article was reported.

Funding: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID

Ji Sook Park  https://orcid.org/0000-0002-4704-2246
References


2. Venter C, O'Mahony L. Immunonutrition: The importance of a new European Academy of Allergy and Clinical Immunology Working Group addressing a significant burden and unmet need. Allergy 2021;00:1-3.


### Tables

#### Table 1. Immunoprotective properties of human milk

<table>
<thead>
<tr>
<th>Immunoprotective properties</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunoglobulins</td>
<td>IgA, secretary IgA, IgG, IgM, IgE</td>
</tr>
<tr>
<td>Immuno-regulatory cytokines</td>
<td>IL6, IL8, TNFα, TGFβ1, TGFβ2</td>
</tr>
<tr>
<td>Growth factors</td>
<td>EGF, TGFα, TGFβ</td>
</tr>
<tr>
<td>Microbiologic factors</td>
<td>Human milk oligosaccharides, probiotic bacteria,</td>
</tr>
<tr>
<td></td>
<td>Latoferrin, Lysozyme</td>
</tr>
<tr>
<td>Others</td>
<td>Medium- and Long-chain polyunsaturated free</td>
</tr>
<tr>
<td></td>
<td>fatty acids</td>
</tr>
</tbody>
</table>

Adjusted from Gregory KE et al\(^7\) and Carr LE et al\(^12\)
Table 2. Main effects of human milk oligosaccharides as immunonutrients

<table>
<thead>
<tr>
<th>Effects of HMOs on infantile immunity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Shaping the gut microbiota</strong></td>
</tr>
<tr>
<td>HMOs stimulate the growth of intestinal microbiota and shape gut microbiota compositions of <em>Bacteroides</em> spp., <em>Clostridium</em> spp., and especially in <em>Bifidobacterium</em> spp. in early life.¹²,³¹,³²</td>
</tr>
<tr>
<td>HMOs modulate the transcriptional activity of <em>B. fragilis</em>, rather than modifying their relative abundance. Another commensal <em>Escherichia coli</em> benefits indirectly by metabolites of <em>B. fragilis</em> upon HMOs degradation.³³</td>
</tr>
<tr>
<td><strong>Antimicrobial and antiviral activities</strong></td>
</tr>
<tr>
<td>HMOs provide antimicrobial or antiviral activities by increasing sensitivity of pathogens, interacting immune cells or inhibiting direct invasion.³⁴-³⁷</td>
</tr>
<tr>
<td>HMOs act as pathogen binding decoys to prevent <em>C. jejuni</em> or Enteropathogenic <em>E. coli</em>, reducing colonization and pathogenicity.³⁸-⁴⁰</td>
</tr>
<tr>
<td><strong>Gut immunity</strong></td>
</tr>
<tr>
<td>HMOs reduce the intestinal permeability by influencing epithelial proliferation and modulating tight junction protein expression via microbiota metabolites such as short-chain fatty acid, development of intestinal glycocalyx, and microorganism-associated molecular patterns (MAMPs) signaling.¹²,⁴¹,⁴²,⁴⁴,⁶⁸</td>
</tr>
</tbody>
</table>

¹²,¹³,¹⁴,¹⁵,¹⁶,¹⁷,¹⁸,¹⁹,²⁰,²¹,²²,²³,²⁴,²⁵,²⁶,²⁷,²⁸,²⁹,³⁰,³¹,³²,³³,³⁴,³⁵,³⁶,³⁷,³⁸,³⁹,⁴⁰,⁴¹,⁴²,⁴³,⁴⁴,⁶⁸
<table>
<thead>
<tr>
<th>Source</th>
<th>Target</th>
<th>Study design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laucirica, 2017</td>
<td>Rotavirus</td>
<td>In vitro experimental study using MA104 cells</td>
<td>The maximum reduction of G1P[8] infectivity in 2’FL (62% reduction, P&lt;0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comparison between experiment and control</td>
<td>The maximum reduction of G2P[4] infectivity with the mixture of 3’SL+6’SL (73% reduction, P&lt;0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2’FL, 3’SL, 6’SL and/or galacto-oligosaccharide were added to MA104 cells infected with human rotavirus G1P[8] and G2P[4]</td>
<td></td>
</tr>
<tr>
<td>Leung, 2020</td>
<td>Upper respiratory tract infection</td>
<td>Double-blinded, randomized controlled trial</td>
<td>Safe in toddlers</td>
</tr>
<tr>
<td></td>
<td>(URTI) and Duration of gastrointestinal tract infection</td>
<td>Clinical trial of different young child formula:</td>
<td>No significant between-group differences on URTI incidence and GITI duration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>YCF-Ref, standard milk formula; YCF-A, milk formula containing Igs, lactoferrin, TGF-β, 2’FL, and milk fat; YCF-B, milk formula containing lower levels of the bioactive proteins in YCF-A; YCF-C, milk formula containing 2’FL</td>
<td></td>
</tr>
<tr>
<td>Autran, 2018</td>
<td>Necrotizing enterocolitis (NEC) in preterm infants</td>
<td>Multicenter prospective clinical cohort study</td>
<td>Lower concentration of Diasialyllacto-N-tetraose (DSLNT) in BM in NEC cases</td>
</tr>
<tr>
<td>Lodge, 2020</td>
<td>Allergic disease (sensitization, wheeze, asthma, and eczema)</td>
<td>Observational cohort study: the Melbourne Atopy Cohort study (high-allergy-risk birth cohort)</td>
<td>Exposure to acidic Lewis HMOs was associated with a higher risk of allergic diseases and asthma (OR asthma at 18 years, 5.82)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colostrum and early lactation milk from 285 mothers</td>
<td>Exposure to the acidic predominant profile was associated with a reduced risk of food sensitization (OR at 12 years, 0.08)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple follow-ups up to age 18 years in offsprings</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comparisons of HMOs contents in BM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comparisons of allergic diseases in offsprings</td>
<td></td>
</tr>
<tr>
<td>Li, 2021</td>
<td>Food allergy</td>
<td>In vivo and in vitro experimental study using allergic mouse model</td>
<td>2’FL dose-dependently inhibited the TLR4/NF-kB inflammatory pathway and upregulated miR-146a expression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral administration of 2’FL or HMO</td>
<td>2’FL reduced β-lactoglobulin allergy via regulation of miR-146a</td>
</tr>
</tbody>
</table>
2′FL, 2′-fucosyllactose; 3′SL, 3′-sialyllactose; 6′SL, 6′-sialyllactose; BM, breast milk; MA104 cells, African green monkey kidney epithelial cells; miR-146a, microRNA 146a; NF-kB, nuclear factor kappa B; OR, odds ratio; TLR4, toll-like receptor 4; VLBW infant, very low birth weight infant; YCF, young child formula.
Table 1. Immunoprotective properties in human milk

<table>
<thead>
<tr>
<th>Immuneoprotective properties</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunoglobulins</td>
<td>IgA, secretary IgA, IgG, IgM, IgE</td>
</tr>
<tr>
<td>Immuno-regulatory cytokines</td>
<td>IL6, IL8, TNFα, TGFβ1, TGFβ2</td>
</tr>
<tr>
<td>Growth factors</td>
<td>EGF, TGFα, TGFβ</td>
</tr>
<tr>
<td>Microbiologic factors</td>
<td>Human milk oligosaccharides, probiotic bacteria, Latoferrin, Lysozyme</td>
</tr>
<tr>
<td>Others</td>
<td>Medium- and Long-chain polyunsaturated free fatty acids</td>
</tr>
</tbody>
</table>

Adjusted from Gregory KE et al\(^7\) and Carr LE et al\(^12\)

Table 2. Main effects of Human milk oligosaccharides as Immunonutrients

<table>
<thead>
<tr>
<th>Effects of HMOs on infantile immunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shaping the gut microbiota</td>
</tr>
<tr>
<td>Antimicrobial and antiviral activities</td>
</tr>
</tbody>
</table>
Gut immunity: HMOs reduce the intestinal permeability by influencing epithelial proliferation and modulating tight junction protein expression via microbiota metabolites such as short-chain fatty acid, development of intestinal glycocalyx, and microorganism-associated molecular patterns (MAMPs) signaling.\textsuperscript{12,41,42,44,68}

Table 3. Recent studies on the prevention of infectious and non-infectious diseases of Human milk oligosaccharides (HMOs)

<table>
<thead>
<tr>
<th>Source</th>
<th>Target</th>
<th>Study design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laucirica, 2017 \textsuperscript{68}</td>
<td>Rotavirus</td>
<td>- In vitro experimental study using MA104 cells</td>
<td>The maximum reduction of G1P[8] infectivity in 2′FL (62% reduction, P&lt;0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Comparison between experiment and control</td>
<td>- The maximum reduction of G2P[4] infectivity with the mixture of 3′SL+6′SL (73% reduction, P&lt;0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 2′FL, 3′SL, 6′SL and/or galacto-oligosaccharide were added to MA104 cells infected with human rotavirus G1P[8] and G2P[4]</td>
<td></td>
</tr>
<tr>
<td>Leung, 2020 \textsuperscript{69}</td>
<td>Upper respiratory tract infection (URTI) and Duration of gastrointestinal tract infection (GITI)</td>
<td>- Double-blinded, randomized controlled trial</td>
<td>Safe in toddlers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Clinical trial of different young child formula: YCF-Ref, standard milk formula; YCF-A, milk formula containing Igs, lactoferrin, TGF-β, 2′FL, and milk fat; YCF-B, milk formula containing containing lower levels of the bioactive proteins in YCF-A; YCF-C, milk formula containing 2′FL</td>
<td>- No significant between-group differences on URTI incidence and GITI duration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 461 healthy Chinese children aged 1-2.5 years</td>
<td></td>
</tr>
<tr>
<td>Author, Year</td>
<td>Condition</td>
<td>Study Design</td>
<td>Key Findings</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Autran, 2018</td>
<td>Necrotizing enterocolitis (NEC) in preterm infants</td>
<td>Multicenter prospective clinical cohort study; 200 mother-VLBW infant pairs; Analyzed HMO composition in BM; NEC (Bell stage 2 or 3)</td>
<td>Lower concentration of Disialyllacto-N-tetraose (DSLNT) in BM in NEC cases</td>
</tr>
<tr>
<td>Lodge, 2020</td>
<td>Allergic disease (sensitization, wheeze, asthma, and eczema)</td>
<td>Observational cohort study: the Melbourne Atopy Cohort study (high-allergy-risk birth cohort); Colostrum and early lactation milk from 285 mothers; Multiple follow-ups up to age 18 years in offsprings; Comparisons of HMOs contents in BM; Comparisons of allergic diseases in offsprings</td>
<td>Exposure to acidic Lewis HMOs was associated with a higher risk of allergic diseases and asthma (OR asthma at 18 years, 5.82); Exposure to the acidic predominant profile was associated with a reduced risk of food sensitization (OR at 12 years, 0.08)</td>
</tr>
<tr>
<td>Li, 2021</td>
<td>Food allergy</td>
<td>In vivo and in vitro experimental study using allergic mouse model; Oral administration of 2`FL or HMO</td>
<td>2<code>FL dose-dependently inhibited the TLR4/NF-kB inflammatory pathway and upregulated miR-146a expression; 2</code>FL reduced β-lactoglobulin allergy via regulation of miR-146a</td>
</tr>
</tbody>
</table>

8 Abbreviations: MA104 cells, African green monkey kidney epithelial cells, 2`FL, 2`-fucosyllactose; 3`SL, 3`-sialyllactose; 6`SL, 6`-sialyllactose; YCF, young child formula; VLBW infant, very low birth weight infant; BM, breast milk; OR, odds ratio; TLR4, toll-like receptor 4; NF-kB, Nuclear factor kappa B; miR-146a, microRNA 146a.